Table 1 Clinicopathological features of colorectal cancers according to the p53 expression status

From: p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy

 

p53-no expression (N=123, 19.8%)

p53-weak expression (N=68, 11.0%)

p53-moderate expression (N=110, 17.7%)

p53-strong expression (N=320, 51.5%)

P

Age, median (min–max)

61 (30–75)

59 (29–78)

62 (31–76)

60 (30–78)

0.956

Sex

    

0.304

 Male

79 (64.2%)

43 (63.2%)

58 (52.7%)

192 (60.0%)

 

 Female

44 (35.8%)

25 (36.8%)

52 (47.3%)

128 (40.0%)

 

Location

    

 < 0.001

 Proximal colon

33 (26.8%)

32 (47.1%)

56 (50.9%)

85 (26.6%)

 

 Distal colon, rectum

90 (73.2%)

36 (52.9%)

54 (49.1%)

235 (73.4%)

 

Gross pattern

    

0.448

 Fungating

73 (59.3%)

46 (67.6%)

72 (65.4%)

190 (59.4%)

 

 Ulcerative

50 (40.7%)

22 (22.4%)

38 (34.6%)

130 (40.6%)

 

Differentiation

    

 < 0.001

 Differentiated

121 (98.4%)

54 (79.4%)

92 (83.6%)

307 (95.9%)

 

 Undifferentiated

2 (1.6%)

14 (20.6%)

18 (16.4%)

13 (4.1%)

 

T category

    

0.818

 T1–3

103 (83.7%)

56 (82.3%)

94 (85.5%)

276 (86.2%)

 

 T4

20 (16.3%)

12 (17.7%)

16 (14.5%)

44 (13.8%)

 

N category

    

 < 0.001

 N0, N1

80 (65.0%)

56 (82.4%)

91 (82.7%)

233 (72.8%)

 

 N2

43 (35.0%)

12 (17.6%)

19 (17.3%)

87 (27.2%)

 

Stage

    

0.001

 II, high-risk

10 (8.1%)

15 (22.1%)

28 (25.5%)

45 (14.1%)

 

 III

113 (91.9%)

53 (77.9%)

82 (74.5%)

275 (85.9%)

 

Lymphovascular invasion

    

0.168

 Absent

72 (58.5%)

41 (60.3%)

60 (54.5%)

157 (49.1%)

 

 Present

51 (41.5%)

27 (39.7%)

50 (45.5%)

163 (50.9%)

 

Perineural invasion

    

0.692

 Absent

86 (69.9%)

51 (75.0%)

86 (78.2%)

231 (72.2%)

 

 Present

37 (30.1%)

17 (25.0%)

24 (21.8%)

89 (27.8%)

 

Extraglandular mucin production

   

 < 0.001

 

 Absent

119 (96.7%)

53 (77.9%)

82 (74.5%)

306 (95.6%)

 

 Present

4 (3.3%)

15 (22.1%)

28 (25.5%)

14 (4.4%)

 

Microsatellite instability

    

 < 0.001

 MSS, MSI-L

118 (95.9%)

50 (74.6%)

93 (86.1%)

311 (97.8%)

 

 MSI-H

2 (1.7%)

17 (25.4%)

15 (13.9%)

7 (2.2%)

 

CIMP

    

 < 0.001

 CIMP-N

118 (97.5%)

57 (85.1%)

94 (86.2%)

304 (95.6%)

 

 CIMP-P1

3 (2.5%)

7 (10.4%)

9 (8.3%)

12 (3.8%)

 

 CIMP-P2

0 (0.0%)

3 (4.5%)

6 (5.5%)

2 (0.6%)

 

MLH1 methylation

    

 < 0.001

 Unmethylated

120 (99.2%)

58 (86.6%)

100 (91.7%)

314 (98.7%)

 

 Methylated

1 (0.8%)

9 (13.4%)

9 (8.3%)

4 (1.3%)

 

CK7 expression

    

0.013

 Not expressed

119 (96.7%)

61 (89.7%)

97 (88.2%)

305 (95.3%)

 

 Expressed

4 (3.3%)

7 (10.3%)

13 (11.8%)

15 (4.7%)

 

CK20 expression

    

0.065

 Retained

112 (91.1%)

56 (82.3%)

91 (82.7%)

288 (90.0%)

 

 Decreased

11 (8.9%)

12 (17.7%)

19 (17.3%)

32 (10.0%)

 

CDX2 expression

    

 < 0.001

 Retained

116 (94.3%)

53 (77.9%)

92 (83.6%)

296 (92.5%)

 

 Decreased

7 (5.7%)

15 (22.1%)

18 (16.4%)

24 (7.5%)

 
Back to article page